Celldex Therapeutics Net Income 2006-2021 | CLDX

Celldex Therapeutics net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Celldex Therapeutics Annual Net Income
(Millions of US $)
2020 $-60
2019 $-51
2018 $-151
2017 $-93
2016 $-129
2015 $-127
2014 $-118
2013 $-82
2012 $-59
2011 $-45
2010 $-3
2009 $-37
2008 $-48
2007 $-15
2006 $-18
2005 $-18
Celldex Therapeutics Quarterly Net Income
(Millions of US $)
2021-09-30 $-20
2021-06-30 $-13
2021-03-31 $-17
2020-12-31 $-22
2020-09-30 $-14
2020-06-30 $-11
2020-03-31 $-13
2019-12-31 $-10
2019-09-30 $-11
2019-06-30 $-12
2019-03-31 $-17
2018-12-31 $-9
2018-09-30 $-7
2018-06-30 $-16
2018-03-31 $-118
2017-12-31 $-4
2017-09-30 $-26
2017-06-30 $-29
2017-03-31 $-34
2016-12-31 $-32
2016-09-30 $-30
2016-06-30 $-32
2016-03-31 $-35
2015-12-31 $-33
2015-09-30 $-32
2015-06-30 $-32
2015-03-31 $-30
2014-12-31 $-32
2014-09-30 $-28
2014-06-30 $-28
2014-03-31 $-30
2013-12-31 $-22
2013-09-30 $-23
2013-06-30 $-19
2013-03-31 $-17
2012-12-31 $-17
2012-09-30 $-15
2012-06-30 $-14
2012-03-31 $-14
2011-12-31 $-13
2011-09-30 $-12
2011-06-30 $-10
2011-03-31 $-10
2010-12-31 $23
2010-09-30 $-9
2010-06-30 $-10
2010-03-31 $-7
2009-12-31 $-13
2009-09-30 $-7
2009-06-30 $-9
2009-03-31 $-8
2008-12-31 $-7
2008-09-30 $-8
2008-06-30 $-10
2008-03-31 $-22
2007-12-31 $-4
2007-09-30 $-4
2007-06-30 $-3
2007-03-31 $-4
2006-12-31 $-6
2006-09-30 $-6
2006-06-30 $-6
2006-03-31 $-3
2005-12-31 $-4
2005-09-30 $-5
2005-06-30 $-5
2005-03-31 $-5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.361B $0.007B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00